

10/670,665

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,  
resulting in a closer connection to BABS  
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display  
fields  
NEWS 5 AUG 02 CAPLUS and CA patent records enhanced with European and Japan  
Patent Office Classifications  
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!  
(Version 7.01 for Windows) now available  
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage  
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal  
status data from INPADOC  
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 12 SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ  
NEWS 13 SEP 27 STANDARDS will no longer be available on STN  
NEWS 14 SEP 27 SWETSCAN will no longer be available on STN  
NEWS 15 SEP 30 STN downtime scheduled October 2-3, 2004

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:13:44 ON 04 OCT 2004

10/670,665

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:14:01 ON 04 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 OCT 2004 HIGHEST RN 756446-64-7

DICTIONARY FILE UPDATES: 3 OCT 2004 HIGHEST RN 756446-64-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10670665.str



chain nodes :

7 8 9 10 11 12 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 6

chain bonds :

1-7 6-10 7-8 7-9 10-11 11-12 12-13 13-14 14-15 15-16 16-17 16-18 18-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

16-17 16-18

exact bonds :

1-7 6-10 7-8 7-9 10-11 11-12 12-13 13-14 14-15 15-16 18-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
19:CLASS

10/670,665

L1 STRUCTURE UPLOADED

=> s l1  
SAMPLE SEARCH INITIATED 17:14:17 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 0 TO 0  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1



=> s l1 ful  
FULL SEARCH INITIATED 17:14:22 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=>  
Uploading C:\STNEXP4\QUERIES\106706651.str



chain nodes :  
7 8 9 10  
ring nodes :  
1 2 3 4 5 6  
chain bonds :  
1-7 6-10 7-8 7-9  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
exact/norm bonds :  
6-10  
exact bonds :  
1-7 7-8 7-9  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,N,Cy,Ak

Match level :

10/670,665

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L4 STRUCTURE UPLOADED

=> s l4

SAMPLE SEARCH INITIATED 17:17:55 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2394 TO ITERATE

41.8% PROCESSED 1000 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 44946 TO 50814  
PROJECTED ANSWERS: 2660 TO 4234

L5 50 SEA SSS SAM L4

=> s l4 ful

FULL SEARCH INITIATED 17:18:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 47267 TO ITERATE

100.0% PROCESSED 47267 ITERATIONS 3775 ANSWERS  
SEARCH TIME: 00.00.01

L6 3775 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	312.94	313.15

FILE 'CAPLUS' ENTERED AT 17:18:10 ON 04 OCT 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Oct 2004 VOL 141 ISS 15  
FILE LAST UPDATED: 3 Oct 2004 (20041003/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

10/670,665

=> s l6

L7 1177 L6

=> s l7 and store operated calcium influx

15294 STORE

22395 STORES

35680 STORE

(STORE OR STORES)

83986 OPERATED

696838 CALCIUM

32 CALCIUMS

696841 CALCIUM

(CALCIUM OR CALCIUMS)

39759 INFLUX

1063 INFLUXES

40283 INFLUX

(INFLUX OR INFLUXES)

45 STORE OPERATED CALCIUM INFLUX

(STORE(W) OPERATED (W) CALCIUM (W) INFLUX)

L8 0 L7 AND STORE OPERATED CALCIUM INFLUX

=> s l7 and calcium

696838 CALCIUM

32 CALCIUMS

696841 CALCIUM

(CALCIUM OR CALCIUMS)

L9 108 L7 AND CALCIUM

=> s l9 and inhibitor

453162 INHIBITOR

471777 INHIBITORS

728228 INHIBITOR

(INHIBITOR OR INHIBITORS)

L10 94 L9 AND INHIBITOR

=> s l10 and SOC

20692 SOC

990 SOCS

21580 SOC

(SOC OR SOCS)

L11 1 L10 AND SOC

=> s l10 and blocking

92971 BLOCKING

30 BLOCKINGS

92990 BLOCKING

(BLOCKING OR BLOCKINGS)

L12 1 L10 AND BLOCKING

=> s l10 and block

202452 BLOCK

78100 BLOCKS

258816 BLOCK

(BLOCK OR BLOCKS)

L13 2 L10 AND BLOCK

=> s l10 and disease

710593 DISEASE

196723 DISEASES

802693 DISEASE

10/670,665

(DISEASE OR DISEASES)

L14 61 L10 AND DISEASE

=> s l10 and inflammat?

185309 INFLAMMAT?

L15 20 L10 AND INFLAMMAT?

=> dup rem l11 l12 l13 l15

PROCESSING COMPLETED FOR L11

PROCESSING COMPLETED FOR L12

PROCESSING COMPLETED FOR L13

PROCESSING COMPLETED FOR L15

L16 21 DUP REM L11 L12 L13 L15 (3 DUPLICATES REMOVED)

=> d l16 ibib hitstr abs 1-21

L16 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:291973 CAPLUS

DOCUMENT NUMBER: 140:309456

TITLE: Perivascular wraps based on biodegradable polymers containing therapeutic agents

INVENTOR(S): Gravett, David M.; Toleikis, Philip M.; Guan, Dechi; Signore, Pierre E.; Spencer, Thomas S.; Hunter, William L.; Wang, Kaiyue

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028583	A2	20040408	WO 2003-US30280	20030926
WO 2004028583	A3	20040819		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004146546	A1	20040729	US 2003-673046	20030926
PRIORITY APPLN. INFO.:			US 2002-414714P	P 20020926
			US 2002-414693P	P 20020927

IT 145599-86-6, Cerivastatin


RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perivascular wraps made of biodegradable polymer mesh containing therapeutic agents for prevention or reduction of proliferative biol. response of passageway or cavity after surgery)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



AB The present invention provides compns., devices, and methods for maintaining or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described. Representative examples of therapeutic agents include microtubule stabilizing agents, anti-angiogenic factors, **inhibitors** of smooth muscle cell growth or proliferation, non-steroidal anti-inflammatory drugs, and other factors useful in preventing and/or reducing a proliferative biol. response that may obstruct or hinder the optimal functioning of the passageway or cavity. For example, perivascular delivery of paclitaxel from mPEG-DL-lactide copolymer-coated PLGA mesh resulted in a dramatic reduction of intimal hyperplasia in a rat balloon injury carotid artery model.

L16 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:100986 CAPLUS

DOCUMENT NUMBER: 140:157460

TITLE: PPAR $\alpha$ -selective chromane and chromene compounds for the treatment of dyslipidemia and other lipid disorders, and preparation thereof

INVENTOR(S): Desai, Ranjit C.; Sahoo, Soumya

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010992	A1	20040205	WO 2003-US23499	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2002-399518P

P 20020730


OTHER SOURCE(S):

MARPAT 140:157460

10/670,665


IT 143201-11-0, Rivastatin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(PPAR $\alpha$ -selective chromane and chromene compds. for treatment of  
lipid disorders, preparation, and use with other agents)  
RN 143201-11-0 CAPLUS  
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-  
methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



● Na

GI



AB A class of chromane and chromene compds. I [R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> = (un)substituted C1-3 alkyl; R<sub>3</sub>, R<sub>5</sub>, R<sub>7</sub> = H, (un)substituted C1-3 alkyl; R<sub>6</sub> = H, Cl, Me, CF<sub>3</sub>; A, B = H, Cl, F, Me, CF<sub>3</sub>; X, Y = O, S; n = 2, 3; dashed line = optional double bond], and pharmaceutically acceptable salts thereof, are useful as therapeutic compds., particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis. Compound preparation is included.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2004:80450 CAPLUS  
DOCUMENT NUMBER: 140:145835

10/670,665

TITLE: Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of the glucocorticoid receptor

INVENTOR(S): Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.; Li, Wenying; Doweiko, Arthur M.; Chen, Xiao-tao; Doweiko, Lidia

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.

SOURCE: PCT Int. Appl., 265 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009017	A2	20040129	WO 2003-US22300	20030717
WO 2004009017	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132758	A1	20040708	US 2003-621909	20030717
PRIORITY APPLN. INFO.:			US 2002-396877P	P 20020718
OTHER SOURCE(S): MARPAT 140:145835				
IT 145599-86-6, Cerivastatin				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of glucocorticoid receptor)				
RN 145599-86-6 CAPLUS				
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



GI



I



II

AB Title compds. I [R-R<sub>4</sub> = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z = carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddn. of methacrylic acid and anthracene (CH<sub>3</sub>CN, EDCI, Et<sub>3</sub>N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, **inflammatory** and immune disorders.

L16 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60341 CAPLUS

DOCUMENT NUMBER: 140:117406

TITLE: Liquid dosage compositions of stable nanoparticulate drugs

INVENTOR(S): Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian

PATENT ASSIGNEE(S): Elan Pharma International, Ltd, Ire.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006959	A1	20040122	WO 2003-US22187	20030716
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRIORITY APPLN. INFO.: US 2002-396530P P 20020716


IT 145599-86-6, Cerivastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(liquid dosage compns. of stable nanoparticulate drugs)

10/670,665

RN 145599-86-6 CAPLUS  
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth **inhibitors** that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth **inhibitor**) to 0.5-3.0% drug.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:41320 CAPLUS

DOCUMENT NUMBER: 140:87743

TITLE: Therapeutic use and pharmaceutical compositions of cholesterol ester transfer protein (CETP) **inhibitors** and optional HMG-CoA reductase **inhibitors** and/or antihypertensive agents

INVENTOR(S): Nguyen, Tu Trung; Shear, Charles Lester; Revkin, James Harold; Ruggeri, Roger Benjamin

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004778	A1	20040115	WO 2003-IB2792	20030618
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,			

10/670,665

MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,  
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG

US 2004053842 A1 20040318 US 2003-459683 20030610  
PRIORITY APPLN. INFO.: US 2002-393395P P 20020702  
OTHER SOURCE(S): MARPAT 140:87743

IT 122254-45-9, Glenvastin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)


(Glenvastatin; therapeutic use and pharmaceutical compns. of  
cholesterol ester transfer protein **inhibitors** and optional  
HMG-CoA reductase **inhibitors** and/or antihypertensive agents)

RN 122254-45-9 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-2-(1-methylethyl)-6-phenyl-3-  
pyridinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 143201-11-0, Rivastatin 145599-86-6, Cerivastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)


(therapeutic use and pharmaceutical compns. of cholesterol ester  
transfer protein **inhibitors** and optional HMG-CoA reductase  
**inhibitors** and/or antihypertensive agents)

RN 143201-11-0 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-  
methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


Double bond geometry as shown.



● Na

RN 145599-86-6 CAPLUS  
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
 Double bond geometry as shown.



AB The invention discloses cholesterol ester transfer protein (CETP) **inhibitors**, pharmaceutical comps. containing such **inhibitors**, and the use of such **inhibitors** to treat certain diseases/conditions, optionally in combination with certain therapeutic agents e.g., antihypertensive agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:451474 CAPLUS

DOCUMENT NUMBER: 141:1258

TITLE: Nitrosated compounds in methods of treating vascular

diseases characterized by nitric oxide insufficiency

INVENTOR(S): Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.;

Worcel, Manuel

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S.

Ser. No. 679,257.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105850	A1	20040603	US 2003-692724	20031027
US 6635273	B1	20031021	US 2000-697317	20001027
US 2004071766	A1	20040415	US 2003-679257	20031007
PRIORITY APPLN. INFO.:			US 1999-162230P	P 19991029
			US 2000-179020P	P 20000131
			US 2000-697317	A1 20001027
			US 2003-679257	A2 20031007


OTHER SOURCE(S): MARPAT 141:1258

IT **145599-86-6D**, Cerivastatin, nitrosated compds.  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (nitrosated compds. in methods of treating vascular diseases  
 characterized by nitric oxide insufficiency)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
 Double bond geometry as shown.



AB The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme **inhibitor**, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated **calcium** channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin **inhibitor**, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress. Nitric oxide action was shown to be impaired in the microvasculature of black hypertensive patients to a greater extent than in white hypertensive patients.

L16 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:392331 CAPLUS  
 DOCUMENT NUMBER: 140:406798  
 TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors**  
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 875,155, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092573	A1	20040513	US 2003-602752	20030624
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	B2 20010606

OTHER SOURCE(S): MARPAT 140:406798

IT 145599-86-6, Cerivastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
 Double bond geometry as shown.



IT 380459-94-9P 380459-96-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 380459-94-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

10/670,665


Absolute stereochemistry.  
Double bond geometry as shown.



● Na

RN 380459-96-1 CAPLUS  
CN [1]Benzoxepino[5,4-b]pyridine-3-heptanoic acid, 4-(4-fluorophenyl)-5,6-dihydro- $\beta$ , $\delta$ -dihydroxy-2-(1-methylethyl)-, monosodium salt, ( $\beta$ R, $\delta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


IT 380460-17-3P 380460-19-5P 380460-21-9P  
380460-23-1P 380460-25-3P 380460-27-5P  
380460-29-7P 380460-31-1P 380460-33-3P  
380460-35-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)


RN 380460-17-3 CAPLUS  
CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)

10/670,665





RN 380460-19-5 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-methanol, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-21-9 CAPLUS



CN [1]Benzoxepino[5,4-b]pyridine, 3-(bromomethyl)-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-23-1 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine, 3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)


10/670,665



RN 380460-25-3 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 380460-27-5 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


10/670,665



RN 380460-29-7 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380460-31-1 CAPLUS

CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/670,665




RN 380460-33-3 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxaldehyde, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-35-5 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X = O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>; Z = HOCHCH<sub>2</sub>CH(OH)CH<sub>2</sub>CO<sub>2</sub>R<sub>3</sub>, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R<sub>1</sub>, R<sub>2</sub> = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R<sub>3</sub> = H, alkyl, metal ion; R<sub>4</sub> = H, halo, CF<sub>3</sub>, etc.; R<sub>7</sub> = H, alkyl, aryl,

alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase **inhibitors** active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

L16 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:913055 CAPLUS

DOCUMENT NUMBER: 139:399770

TITLE: Medical goods comprising heparin or chitosan-based hemocompatible coating

INVENTOR(S): Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PATENT ASSIGNEE(S): Hemoteg G.m.b.H., Germany

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094990	A1	20031120	WO 2003-DE1253	20030415
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10221055	A1	20031127	DE 2002-10221055	20020510
DE 10261986	A1	20040318	DE 2002-10261986	20020510
PRIORITY APPLN. INFO.:			US 2002-378676P	P 20020509
			DE 2002-10221055	A 20020510

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medical goods comprising a heparin-based hemocompatible coating)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:892539 CAPLUS

DOCUMENT NUMBER: 139:375605

TITLE: Synthesis and uses of 4-azasteroid derivatives as selective androgen receptor modulators (SARMs)

INVENTOR(S): Wang, Jiabing; McVean, Carol A.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 181 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092588	A2	20031113	WO 2003-US13120	20030425
WO 2003092588	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				

10/670,665

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,  
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-376779P

P 20020430

OTHER SOURCE(S): MARPAT 139:375605

IT 145599-86-6, Cerivastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)


(in addition to SARMS treatment; synthesis and uses of 4-azasteroid  
derivs. as selective androgen receptor modulators (SARMS) in the  
treatment of androgen deficiency-related diseases)

RN 145599-86-6 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-  
methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



GI



AB Compds. of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compds. are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other

hematopoietic disorders, **inflammatory** arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

L16 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757525 CAPLUS

DOCUMENT NUMBER: 139:277056

TITLE: Preparation of fluorinated 4-aza-androstan-3-one-17 $\beta$ -carboxamide derivatives as androgen receptor modulators

INVENTOR(S): Meissner, Robert S.; Perkins, James J.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077919	A1	20030925	WO 2003-US8277	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-363822P P 20020313

OTHER SOURCE(S): MARPAT 139:277056

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bone strengthening agents as adjuvant therapeutics; preparation of fluorinated 4-aza-androstan-3-one-17 $\beta$ -carboxamide derivs. as androgen receptor modulators and their therapeutic uses)

RN 145599-86-6 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



GI



AB Fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs., such as I [a-b = CF:CH, CHFCH<sub>2</sub>, CF<sub>2</sub>CH<sub>2</sub>; R<sup>1</sup> = H, CH<sub>2</sub>OH, (un)substituted alkyl; R<sup>2</sup> = H, alkyl; R<sup>3</sup> = alkyl, cycloheteroalkyl, aryl, heteroaryl; R<sup>2</sup>R<sup>3</sup> = 5 or 6-membered ring fused with a 5- or 6-membered aromatic ring system having 0-2 heteroatoms], or a pharmaceutically acceptable salt or an enantiomer thereof, were prepared for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, 4-aza-androstan-3-one-17β-carboxamide derivative II, was prepared via a multiple step reaction sequence starting from 4-methyl-4-aza-androstan-3-one-17-carboxylic acid Me ester and 2-fluoro-benzylamine. The prepared compds. are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. I are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, **inflammatory** arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:377132 CAPLUS

DOCUMENT NUMBER: 138:367144

TITLE: Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases

INVENTOR(S): Schoenbeck, Uwe; Ridker, Paul M.; Libby, Peter

PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


10/670,665

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040691	A2	20030515	WO 2002-US35505	20021105
WO 2003040691	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003152566	A1	20030814	US 2002-288253	20021105
EP 1451577	A2	20040901	EP 2002-780578	20021105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-338841P	P 20011105
			WO 2002-US35505	W 20021105

IT 145599-86-6, Cerivastatin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(soluble CD40L as prognostic marker of atherosclerotic diseases, and use in therapeutic agent assessment)  
RN 145599-86-6 CAPLUS  
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



AB The invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases, e.g. myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, the invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.


L16 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2003:261603 CAPLUS

10/670,665


DOCUMENT NUMBER: 138:281598  
TITLE: Androstane compounds as androgen receptor (AR) modulators for the treatment of AR-related diseases  
INVENTOR(S): Wang, Jiabing  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026568	A2	20030403	WO 2002-US29436	20020917
WO 2003026568	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1429779	A2	20040623	EP 2002-766288	20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-324124P	P 20010921
			WO 2002-US29436	W 20020917
OTHER SOURCE(S):		MARPAT 138:281598		
IT	145599-86-6, Cerivastatin			
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(androstane compds. as androgen receptor (AR) modulators in conjunction with bone-strengthening agents for treatment of AR-related diseases)			
RN	145599-86-6 CAPLUS			
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



GI



AB Comps. of structural formula (I) as herein defined are claimed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compds. are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, **inflammatory** arthritis and joint repair, alone or in combination with other active agents. Methods for the co-administration of those compds. with bone-strengthening agents are also claimed.

L16 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:927184 CAPLUS

DOCUMENT NUMBER: 138:14048

TITLE: Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.

INVENTOR(S): Cheng, Peter T.; Jeon, Yoon; Wang, Wei

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523
WO 2002096357	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

10/670,665

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
US 2003092697 A1 20030515 US 2002-153342 20020522  
EP 1401433 A2 20040331 EP 2002-737192 20020523  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
PRIORITY APPLN. INFO.: US 2001-294505P P 20010530  
WO 2002-US16628 W 20020523

OTHER SOURCE(S): MARPAT 138:14048


IT 145599-86-6, Cerivastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coadministration; preparation of oxazolylethoxyphenylprolines and related  
comps. as antidiabetic and antiobesity agents)

RN 145599-86-6 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-  
methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



GI

I



L16 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

DOCUMENT NUMBER: 137:109267

INVENTOR(S) : Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing

PATENT ASSIGNEE(S) : USA

SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

Page 30

10/670,665

US 2002013334  
PRIORITY APPLN. INFO.:

A1 20020131

US 2001-875155  
US 2000-211595P  
US 2001-875155

20010606  
P 20000615  
A2 20010606

OTHER SOURCE(S): MARPAT 137:109267

IT 145599-86-6, Cerivastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA  
reductase **inhibitors** for treatment of hyperlipidemia,  
hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other  
disorders)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-  
methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



IT 380459-94-9P 380459-96-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors**  
for treatment of hyperlipidemia, hypercholesterolemia,  
hypertriglyceridemia, atherosclerosis, and other disorders)

RN 380459-94-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-  
methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]-3,5-dihydroxy-, monosodium  
salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




● Na

RN 380459-96-1 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-heptanoic acid, 4-(4-fluorophenyl)-5,6-dihydro-β,δ-dihydroxy-2-(1-methylethyl)-, monosodium salt, (βR,δR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 380460-17-3P 380460-19-5P 380460-21-9P

380460-23-1P 380460-25-3P 380460-27-5P

380460-29-7P 380460-31-1P 380460-33-3P

380460-35-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)


RN 380460-17-3 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



10/670,665



RN 380460-19-5 CAPLUS  
CN [1]Benzoxepino[5,4-b]pyridine-3-methanol, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 380460-21-9 CAPLUS  
CN [1]Benzoxepino[5,4-b]pyridine, 3-(bromomethyl)-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-23-1 CAPLUS  
CN [1]Benzoxepino[5,4-b]pyridine, 3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/670,665




RN 380460-25-3 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 380460-27-5 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 380460-29-7 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380460-31-1 CAPLUS

CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/670,665




RN 380460-33-3 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxaldehyde, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-35-5 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X = O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>; Z = HOCHCH<sub>2</sub>CH(OH)CH<sub>2</sub>CO<sub>2</sub>R<sub>3</sub>, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R<sub>1</sub>, R<sub>2</sub> = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R<sub>3</sub> = H, alkyl, metal ion; R<sub>4</sub> = H, halo, CF<sub>3</sub>, etc.; R<sub>7</sub> = H, alkyl, aryl,

alkanoyl, aroyl, alkoxycarbonyl, etc.; R<sub>9</sub>, R<sub>10</sub> = H, alkyl], were prepared as HMG CoA reductase **inhibitors** active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

L16 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:392237 CAPLUS

DOCUMENT NUMBER: 136:401651

TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase **inhibitors**

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061901	A1	20020523	US 2001-8154	20011204
US 6620821	B2	20030916		
US 2002028826	A1	20020307	US 2001-875218	20010606
US 2004024216	A1	20040205	US 2003-602753	20030624
PRIORITY APPLN. INFO.:			US 2000-211594P	P 20000615
			US 2001-875218	A2 20010606
			US 2001-8154	A3 20011204

OTHER SOURCE(S): MARPAT 136:401651

IT 380469-07-8P 380469-08-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of fused pyridine derivs. as HMG-CoA reductase **inhibitors**)

RN 380469-07-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 380469-08-9 CAPLUS

10/670,665


CN L-Arginine, mono[(3R,5S,6E)-7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-6-heptenoate] (9CI) (CA INDEX NAME)

CM 1

CRN 380469-07-8

CMF C30 H32 F N O4

Absolute stereochemistry.  
Double bond geometry as shown.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



IT 380468-71-3P 380468-73-5P 428863-94-9P  
428876-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 380468-71-3 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

10/670,665




● Na

RN 380468-73-5 CAPLUS

CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-heptanoic acid,  
4-(4-fluorophenyl)-6,7-dihydro- $\beta$ , $\delta$ -dihydroxy-2-(1-methylethyl)-  
, monosodium salt, ( $\beta$ R, $\delta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 428863-94-9 CAPLUS

CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-heptanoic acid,  
4-(4-fluorophenyl)-6,7-dihydro- $\beta$ , $\delta$ -dihydroxy-2-(1-methylethyl)-  
, ( $\beta$ R, $\delta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/670,665




RN 428876-96-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● 1/2 Ca


IT 135427-12-2P 135454-77-2P 137586-44-8P  
380464-21-1P 380468-91-7P 380468-93-9P  
380468-95-1P 380468-97-3P 380468-99-5P  
380469-01-2P 380469-05-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 135427-12-2 CAPLUS


CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-carboxaldehyde, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/670,665




RN 135454-77-2 CAPLUS

CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-methanol, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 137586-44-8 CAPLUS



CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 380464-21-1 CAPLUS


CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine, 3-(bromomethyl)-4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/670,665



RN 380468-91-7 CAPLUS


CN Phosphonic acid, [[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 380468-93-9 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 380468-95-1 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-

10/670,665



methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 380468-97-3 CAPLUS

CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine, 3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 380468-99-5 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/670,665




RN 380469-01-2 CAPLUS  
CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380469-05-6 CAPLUS  
CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-acetic acid, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)




IT 145599-86-6, Cerivastatin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic compns. also containing; preparation of fused pyridine derivs.  
as HMG-CoA reductase inhibitors)

10/670,665


RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



GI



AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH<sub>2</sub>CR<sup>7</sup>(OH)CH<sub>2</sub>CO<sub>2</sub>R<sup>3</sup> or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH<sub>2</sub>)<sub>x</sub> and/or (CH<sub>2</sub>)<sub>y</sub> together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R<sup>1</sup>, R<sup>2</sup> = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R<sup>3</sup> = H or lower alkyl; R<sup>4</sup> = H, halo, CF<sub>3</sub>, OH, alkyl, alkoxy, CO<sub>2</sub>H, (un)substituted NH<sub>2</sub>, cyano, (un)substituted CONH<sub>2</sub>, etc.; R<sup>7</sup> = H, alkyl]. The compds. are HMG-CoA reductase **inhibitors**, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Preps. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner

similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as **inhibitors** of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

L16 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:51509 CAPLUS

DOCUMENT NUMBER: 139:159743

DOCUMENT NUMBER: 10110001  
TITLE: Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis

AUTHOR(S) : Kalinowski, L.; Dobrucki, I. T.; Malinski, T.

CORPORATE SOURCE: Department of Laboratory Medicine, Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science, Medical University of Gdansk, Gdansk, Pol.

SOURCE: Journal of Physiology and Pharmacology (2002), 53(4, Pt. 1), 585-595

CODEN: JPHPEI; ISSN: 0867-5910

PUBLISHER: Polish Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 145599-86-6, Cerivastatin

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB Endothelium dysfunction, which is often defined as a decrease in NO bioavailability, is one of the earliest manifestations of endothelium-impaired function disorders, including atherosclerosis. Although improvement in NO bioavailability has been attributed to the lowering of serum cholesterol levels, recent studies suggest that HMG-CoA reductase **inhibitors**, statins, may have direct effects on NO bioavailability by little known mechanisms that are independent of serum cholesterol levels. The long-term effect of cerivastatin on NO release from endothelial cells was determined by using highly sensitive electrochem. microensors and was correlated with endothelial NO synthase (eNOS) levels. To explore whether changes in isoprenoid synthesis affect NO bioavailability and eNOS expression, human endothelial cells were treated with cerivastatin, L-mevalonate (MVA; 1.5 mmol/L),

geranylgeranylpyrophosphate (GGPP; 1 mg/mL) and farnesylpyrophosphate (FPP; 1 mg/mL). Cerivastatin increased spontaneous (by 53%  $\pm$  6) and an eNOS-stimulated NO release (by 41  $\pm$  6% for calcium ionophore and by 47 $\pm$ 5% acetylcholine) as well as eNOS expression (by 118  $\pm$  6%) in the same concentration-range. Cerivastatin-dependent increase in both NO release and eNOS expression was revealed after .apprx.4 h of exposure reaching the maximum after .apprx.10 h. Co-treatment with MVA or GGPP, but not FPP or LDL, reversed the effects of cerivastatin. These findings indicate that the long-term effect of cerivastatin resulting in enhanced NO bioavailability in endothelial cell is, at least in part, due to up-regulation of eNOS by **blocking** isoprenoids synthesis.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:338762 CAPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105  
US 2000-196571P P 20000411

IT 145599-86-6, Cerivastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical

agent


from gene expression profile)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

L16 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3  
 ACCESSION NUMBER: 2001:396644 CAPLUS  
 DOCUMENT NUMBER: 135:24671  
 TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions  
 INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing  
 PATENT ASSIGNEE(S): Lipocine, Inc., USA  
 SOURCE: PCT Int. Appl., 107 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 12  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6248363	B1	20010619	US 1999-447690	19991123

10/670,665

EP 1233756 A1 20020828 EP 2000-980761 20001122  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
JP 2003517470 T2 20030527 JP 2001-539423 20001122  
PRIORITY APPLN. INFO.: US 1999-447690 A 19991123  
WO 2000-US32255 W 20001122

IT 145599-86-6, Cerivastatin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid carriers for improved delivery of active ingredients in  
pharmaceutical compns.)  
RN 145599-86-6 CAPLUS  
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-  
methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:661287 CAPLUS

DOCUMENT NUMBER: 135:216008

TITLE: P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine

INVENTOR(S): Tanida, Norifumi; Goto, Takeshi; Kurosaki, Yuji

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064253	A1	20010907	WO 2001-JP1546	20010301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001036009	A5	20010912	AU 2001-36009	20010301
EP 1260233	A1	20021127	EP 2001-908178	20010301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003158097	A1	20030821	US 2002-220551	20021121
PRIORITY APPLN. INFO.:			JP 2000-57630	A 20000302
			WO 2001-JP1546	W 20010301

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(P-glycoprotein modifiers for drug delivery to intestine)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



AB Disclosed are novel medicinal compns. aiming at delivering a medicine to a specific site of the large intestine; and preps. for intestinal administration with the use of the same. P-glycoprotein enhancers and **inhibitors** in the compns. allow specific drug delivery in the lower or upper intestine. A tablet was formulated containing betamethasone sodium phosphate 2, verapamil (as P-glycoprotein **inhibitor**) 1, crystalline cellulose 10, lactose 81, crospovidone 5, and Mg stearate 1 part was coated with a coating composition containing Eudragit E 7, ethanol 70, water 19.5, and talc 3.5 parts.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:283949 CAPLUS

DOCUMENT NUMBER: 134:311218

TITLE: Synthesis and use of heterocyclic sodium/proton

exchange inhibitors  
 INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 221 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002
WO 2001027107	A3	20020124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1224183	A2	20020724	EP 2000-968723	20001002
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
BR 2000014725	A	20030617	BR 2000-14725	20001002
JP 2003527331	T2	20030916	JP 2001-530325	20001002
NO 2002001717	A	20020610	NO 2002-1717	20020411
PRIORITY APPLN. INFO.:			US 1999-158755P	P 19991012
			WO 2000-US27461	W 20001002

OTHER SOURCE(S): MARPAT 134:311218

IT 145599-86-6, Cerivastatin


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)


RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
 Double bond geometry as shown.



GI



AB Compds. of formula I [wherein; n is 1-5; X is N or CR<sup>5</sup>, where R<sup>5</sup> is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R<sup>1</sup> is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)<sub>3</sub>Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are any of the groups set out for R<sup>1</sup> and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R<sup>1</sup> is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding  $\alpha$ -chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents,  $\beta$ -adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

L16 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:167849 CAPLUS  
 DOCUMENT NUMBER: 134:217194  
 TITLE: Systemic **inflammatory** markers as diagnostic tools in the prevention of atherosclerotic diseases  
 INVENTOR(S): Ridker, Paul; Hennekens, Charles H.  
 PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015744	A1	20010308	WO 2000-US24251	20000831
WO 2001015744	C2	20020926		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1212101	A1	20020612	EP 2000-959851	20000831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

10/670,665

JP 2003508453 T2 20030304 JP 2001-520155 20000831  
PRIORITY APPLN. INFO.: US 1999-387028 A 19990831  
WO 2000-US24251 W 20000831

IT 145599-86-6, Cerivastatin  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of agents and systemic **inflammatory** markers to predict and inhibit cardiovascular disorders in humans)  
RN 145599-86-6 CAPLUS  
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.



AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder such as atherosclerosis, stroke, and myocardial infarction by assessing the level of systemic **inflammation** marker (such as sICAM or C-reactive protein) in an individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorders; and of drug combinations (anti-**inflammatory** agents, lipid-reducing agents, angiotensin system **inhibitors**, **calcium** channel blockers,  $\beta$ -adrenergic receptor blockers) suitable for prevention future cardiovascular disease.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
126.14	439.29

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-14.70	-14.70

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:26:23 ON 04 OCT 2004